Uncertainties Surround Optimal Dosing of Cytarabine in AML
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
A review of 13 cases of MPN in younger patients sought to determine whether pegylated interferon, used to treat adult patients with these diseases, was appropriate for patients younger than 21.
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
Investigators assessed the effectiveness of integrated palliative and oncology care on end-of-life outcomes in patients with acute myeloid leukemia.
Investigators aimed to understand how well adolescents with cancer understand their prognosis compared with their health care providers and caregivers.
This retrospective analysis explored the impact of beta blocker therapy on survival in patients with relapsed or refractory multiple myeloma receiving pomalidomide.
For patients with relapsed or refractory multiple myeloma, subcutaneous bortezomib may improve the tolerability of combination panobinostat, bortezomib, and dexamethasone.
The approval was based on data from the BOSTON trial that assessed Xpovio in combination with bortezomib and dexamethasone in 402 adults with relapsed or refractory multiple myeloma who had received 1 to 3 prior therapies.